Cargando…
Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling
Circulating tumor DNA (ctDNA) analysis is being incorporated into cancer care; notably in profiling patients to guide treatment decisions. Responses to targeted therapies have been observed in patients with actionable mutations detected in plasma DNA at variant allele fractions (VAFs) below 0.5%. Hi...
Autores principales: | Plagnol, Vincent, Woodhouse, Samuel, Howarth, Karen, Lensing, Stefanie, Smith, Matt, Epstein, Michael, Madi, Mikidache, Smalley, Sarah, Leroy, Catherine, Hinton, Jonathan, de Kievit, Frank, Musgrave-Brown, Esther, Herd, Colin, Baker-Neblett, Katherine, Brennan, Will, Dimitrov, Peter, Campbell, Nathan, Morris, Clive, Rosenfeld, Nitzan, Clark, James, Gale, Davina, Platt, Jamie, Calaway, John, Jones, Greg, Forshew, Tim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854321/ https://www.ncbi.nlm.nih.gov/pubmed/29543828 http://dx.doi.org/10.1371/journal.pone.0193802 |
Ejemplares similares
-
Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA
por: Gale, Davina, et al.
Publicado: (2018) -
Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer
por: Pritchett, Michael A., et al.
Publicado: (2019) -
Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non–Small-Cell Lung Cancer
por: Remon, Jordi, et al.
Publicado: (2019) -
Development of a non-infectious encapsidated positive control RNA for molecular assays to detect foot-and-mouth disease virus
por: Madi, Mikidache, et al.
Publicado: (2015) -
Dynamics of multiple resistance mechanisms in plasma DNA during EGFR‐targeted therapies in non‐small cell lung cancer
por: Tsui, Dana Wai Yi, et al.
Publicado: (2018)